Morgan Stanley Adjusts Foghorn Therapeutics Price Target to $9 From $6, Maintains Equalweight Rating
Morgan Stanley Adjusts Foghorn Therapeutics Price Target to $9 From $6, Maintains Equalweight Rating
摩根士丹利将foghorn therapeutics的目标股价从6美元调整为9美元，保持中性评级
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间